Basilea Pharmaceutica - Zevtera (ceftobiprole) clinical data published
Basilea has announced that the results from its Phase III trial (ERADICATE) for ceftobiprole have been published the New England Journal of...
276 Views
Basilea Pharmaceutica - A strong start to FY23 across the board
Basilea announced strong H123 results, including revenues for Cresemba, and in August submitted a new drug application (NDA) to the US FDA for...
341 Views
Basilea Pharmaceutica - Zevtera back on track: NDA submitted to the FDA
Basilea has announced that it has filed its new drug application (NDA) for Zevtera (ceftobiprole) with the FDA. As part of this submission, the...
110 Views
Basilea Pharmaceutica - Prompt receipt of milestone payments for Cresemba
Basilea has announced receipt of two separate sales-related milestone payments totalling US$26.25m (CHF23.7m) from licensing partner Pfizer. The...
263 Views
Basilea Pharmaceutica - Zevtera NDA submission pushed to Q323
Basilea has announced that there will be a minor delay in the timing of its new drug application (NDA) for Zevtera (ceftobiprole) to the FDA and it...
255 Views